Phase I Multicenter Trial Of Cudc-907 In Children And Young Adults With Relapsed/Refractory Solid Tumors, Cns Tumors, And Lymphomas.

David Stephen Shulman,Cecilia Carlowicz,Clay Gustafson,Kieuhoa Tran Vo,Elizabeth Fox,Jodi Ann Muscal,Jeffrey G. Supko,Andrew E. Place,Susan N. Chi,Suzanne Shusterman,Gina Hanna,Jane O'Brien,Suzanne Ezrre,Pei-Chi Kao,Wendy B. London,Steven G. Dubois

JOURNAL OF CLINICAL ONCOLOGY（2018）

Cited 4|Views12

No score

Abstract

10542Background: CUDC-907 is a first-in-class small molecule inhibitor of histone deacetylases and phosphatidylinositol-3-kinases. Data from pediatric preclinical models, and adult clinical studies...

Translated text

Key words

HDAC Inhibitors

AI Read Science

Must-Reading Tree

Example

Generate MRT to find the research sequence of this paper

Chat Paper

Summary is being generated by the instructions you defined